Member Info for Titania

https://dcricollab.dcri.duke.edu/sites/NIHKR/KR/GR-Slides-07-15-22.pdf?Mobile=1&Source=%2Fsites%2FNIHKR%2F%5Flayouts%2F15%2Fmobile%2Fviewa%2Easpx%3FList%3D0095518e%2D671d%2D407a%2Da6a8%2De84adfd1316e%26View%3D951b53bd%2Deaa1%2D4b63%2Da07a%2D87223a14d83f%26ViewMode%3DDetail%26wdFCCState%3D1

For those who haven't seen this yet. Apologies if already posted.

https://businessmag.co.uk/technology-innovation/kent-researchers-help-to-develop-future-covid-19-drugs/

https://pharmaphorum.com/news/pfizer-seeks-to-overturn-three-rsv-vaccine-patents-held-by-gsk/

"In the US alone, RSV infections account for approximately 177,000 hospitalisations and 14,000 deaths each year among older adults, according to Pfizer."

Glad SSH thinks we can be part of the RSV solution.

https://www.forbes.com/sites/williamhaseltine/2022/06/21/biggest-risk-factor-for-severe-covid-19-other-than-age-autoantibodies/?sh=3d115d4e7124

Apologies if already posted.

https://www.theamericanconservative.com/articles/biden-pays-big-bucks-for-pfizers-latest-flop/

"If you register for this event you acknowledge that LSEG will pass your information to the event host, Synairgen PLC and Consilium Strategic Communications, for the purposes of carrying out the event. The event host will be a separate data controller of any personal information received from LSEG. For more information on how the event host uses your data, please see their privacy policy."

There seemed to be nothing much new in the presentation apart from confirmation of the cash figures. Good way to collect investors emails though!

https://synairgen.vercel.app/careers

"In 2011, one of his patients, a two-year-old French girl, was hospitalized with a severe case of the common flu. Stuggling to breathe, the previously healthy toddler had such acute symptoms that Casanova had a hunch that genetics may be in play. “Infectious diseases of childhood, once thought to be archetypical environmental diseases, actually may be among the most genetically predetermined conditions of mankind,” writes Casanova in a 2015 paper in the Proceedings of the National Academy of Sciences. By sequencing her genome, he found that the girl had mutations on the gene coding for a protein that activates the body’s response to flu viruses, called interferon. In the cells lining her lungs, where the flu virus attacks, she lacked interferon, rendering her unable to fight off the infection."

https://www.pfizer.com/news/articles/got_the_flu_it_may_be_because_of_your_genes

https://www.sciencedaily.com/releases/2022/05/220517151820.htm

Apologies if already posted.

"But there have been cases of people who received the drug and completed the five-day regimen who then had a rebound of symptoms."

https://www.pharmalive.com/why-pfizer-may-be-holding-paxlovid-close-to-the-chest/

Apologies if already posted.

Management did say that the April run rate was marginally ahead: “However, investor confidence remains relatively fragile given continued inflation concerns and geopolitical uncertainty, therefore, the Capital markets outlook remains difficult to predict.” The same could be said for both equities and trading which saw declines of 43 per cent and 22 per cent, respectively. Trading was adversely affected by the volatility caused by Russia’s invasion of Ukraine, while equities suffered both from market declines and reduced investor confidence. One area that did hold up well was advisory, which delivered 38 per cent growth to £17.2mn for the half, which relies on a pipeline of completing M&A deals.

https://www.investorschronicle.co.uk/news/2022/05/10/tough-times-at-numis/

"One that the international conference committee organizes and has now I think in its third year with the conference is the Clinical Trials Symposium that is a really exciting session where we ask large phase 2 and phase 3 trials to submit proposals for talks."

"And then we select from a fairly large list, the ones that are most intriguing that we think will have the greatest impact on practice going forward, so I'm pleased to say we've got 4 this year, that will be featuring one of those on pediatric and adult asthma, another on treatment of COVID, so the prevention of severe disease, another one on updates or new advances in bronchiectasis treatment, and the fourth trial that'll be featured in that session relates to new therapy, a novel small molecule for treatment of idiopathic pulmonary fibrosis, so that'll be a great addition to the repertoire of treatment for that disorder. We've got some other clinical events that are... Or clinical sessions that are really highlights. We have 3 sessions, including one that is strictly focused on pediatrics, that would fall under the fellow's case report category, so these are fellows presenting cases with expert feedback, very important for these members in training to get that feedback and exposure. And it's usually a great audience participation thing where you can get inside the minds of some of the leaders in pulmonary medicine."

https://www.consultant360.com/hot-topics-ats-2022

Dr. Cameron Wolfe, an infectious disease specialist at Duke University Hospital, advises getting a test as soon as you have symptoms of COVID-19.

"If you wait until you have started to get breathless, you have already to a large extent missed the window where these drugs will be helpful," Wolfe said.

Read more at:
https://economictimes.indiatimes.com/magazines/panache/covid-pills-are-here-but-they-arent-for-everyone-find-out-if-you-should-take-this-medication/articleshow/91114058.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Apologies if this has already been posted.

I note the SNG stall is next to the FUN station!

"This session will provide late-breaking information on leading clinical trials affecting the pulmonary, critical care and sleep community."

https://www.abstractsonline.com/pp8/#!/10476/session/432

I wonder what the definition of late/breaking is?

"Respiratory drug development and commercialisation encompass improvements in existing classes of systemic and inhaled treatments as well as novel agents for common and rare respiratory conditions. Finding effective and safe new classes of drugs to treat asthma and COPD remains difficult. tranScrip teams have expertise in all major respiratory indications from asthma, COPD, allergy and COVID-19 to orphan indications such as cystic fibrosis or idiopathic pulmonary fibrosis. We are helping our clients address clinical and regulatory challenges, differentiate their products and realise their drug development and lifecycle goals."

Synairgen use Transcrip services

I was pleased to see that Monika Kraft served as president of the American Thoracic Society in 2012-13.

2hrs and 12 people to discuss something of substance no doubt.

Participant
P. Monk1, T. Wilkinson2, J. Brookes1, T. Batten3, V. Tear1, M. Mankowski4, F. Gabbay4, D. Davies5, C. Brightling6, M. Kraft7, R. Djukanovic8, S. Holgate8;
1Synairgen Research Limited, Southampton, United Kingdom, 2NIHR Biomedical Research centre UHS NHS FT, Southampton, United Kingdom, 3Veramed Limited, 5th Floor Regal House, 70 London Road,, Twickenham, United Kingdom, 4TranScrip, Wokingham, United Kingdom, 5School of Medicine, University of Southampton, Southampton, United Kingdom, 6University of Leicester, Leicester, United Kingdom, 7Univ of Arizona Health Sciences Center, Tucson, AZ, United States, 8Southampton General Hospital, Southampton, United Kingdom
Abstract
Abstract is embargoed at this time.